1.
Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of ezetimbe/simvastatin versus simvastatin monotherapy on card...
by Cannon, Christopher P., MD
The American heart journal, 2008, Vol.156 (5), p.826-832
2.
Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: Final baseline characteristics of the IMPRO...
by Blazing, Michael A., MD
The American heart journal, 2014, Vol.168 (2), p.205-212.e1
3.
An update on the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design
by Califf, Robert M., MD
The American heart journal, 2010, Vol.159 (5), p.705-709
4.
On-Treatment Analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT)
by Blazing, Michael A., MD
The American heart journal, 2016, Vol.182, p.89-96
5.
Outcomes of Patients With Acute Coronary Syndrome and Previous Coronary Artery Bypass Grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI...
by Brilakis, Emmanouil S., MD, PhD
The American journal of cardiology, 2008, Vol.102 (5), p.552-558
6.
Effect of Intensive Lipid-Lowering Therapy on Mortality After Acute Coronary Syndrome (a Patient-Level Analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation...
by Murphy, Sabina A., MPH
The American journal of cardiology, 2007, Vol.100 (7), p.1047-1051
7.
Estimated glomerular filtration rate, inflammation, and cardiovascular events after an acute coronary syndrome
by Mielniczuk, Lisa M., MD
The American heart journal, 2008, Vol.155 (4), p.725-731
8.
Effect of statin dose on incidence of atrial fibrillation: Data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 (PROV...
by McLean, Dalton S., MD
The American heart journal, 2008, Vol.155 (2), p.298-302
